The high agreement between results from the PCR, the cobas EZH2 Test, and MiSeq, as well as the low invalid rate were consistent between the method correlation study run with commercial NHL samples and the method comparison study run with therapeutic trial clinical patient samples. This evidence concerns the gene EZH2 and non-Hodgkin lymphoma.